Japan Age-Related Macular Degeneration (AMD) Market to Reach US$ 897.79 Million by 2033, Driven by Aging Population and Innovative Therapies

Japan Age-Related Macular Degeneration (AMD) Market Overview

According to Renub Research Project Report Japan Age-Related Macular Degeneration (AMD) Market is expected to grow from US$ 526.46 million in 2024 to US$ 897.79 million by 2033, at a CAGR of 6.11%. AMD, a leading cause of vision loss in older adults, is increasingly prevalent due to Japan’s aging population.

With technological advancements in diagnostic imaging and ophthalmic care, early detection and treatment are improving outcomes. Pharmaceutical and biotech companies are actively developing innovative therapies, ranging from anti-VEGF injections to gene and regenerative treatments, making Japan a dynamic market for AMD care.

Despite growth opportunities, challenges such as high treatment costs, limited rural access, and reimbursement complexities persist, particularly for novel therapies. Public awareness campaigns and government support for healthcare innovation are expected to further drive market expansion.

👉 Want to explore detailed market trends, segment insights, and forecasts? 🔗 Request Free Sample Report

Key Growth Drivers

1. Aging Population and Increasing AMD Prevalence

Japan has one of the highest proportions of elderly individuals worldwide, making age-related eye diseases a critical healthcare priority. The risk of AMD increases with age, prompting greater demand for early diagnosis, effective treatment, and long-term management. Government programs and ophthalmologists are focusing on screening and patient education, reinforcing the growing need for AMD therapies.

2. Advancements in Diagnostic Technologies

Technological innovation is a major factor in market growth. Optical coherence tomography (OCT), fundus photography, and fluorescein angiography enable earlier and more accurate detection of AMD, improving treatment outcomes. Integration of AI and telemedicine is facilitating remote diagnosis and patient monitoring, expanding access and effectiveness, especially in urban centers.

3. Launch of Innovative Medicines

The development of gene therapies, regenerative medicine, and long-acting anti-VEGF treatments is expanding therapeutic options for wet and dry AMD. Collaborative research between Japanese and international pharmaceutical companies, supported by expedited regulatory approval, is accelerating the introduction of novel treatments. These innovations aim to enhance efficacy, reduce injection frequency, and minimize side effects, driving patient adherence and market growth.

Market Challenges

1. High Medical Costs and Reimbursement Issues

Advanced treatments, including gene therapy and anti-VEGF injections, remain expensive, posing challenges even under Japan’s universal healthcare system. Co-payments, reimbursement complexities, and procedural delays can limit access for elderly patients, impacting therapy adherence and treatment outcomes.

2. Limited Rural Accessibility and Awareness

While urban centers benefit from advanced ophthalmic care, rural regions face limited access to diagnostic tools and specialists. Lack of awareness about AMD symptoms and early interventions further exacerbates late-stage presentations. Expanding telemedicine, mobile clinics, and educational programs is crucial for equitable care.

Regional Market Insights

Tokyo AMD Market

As Japan’s capital, Tokyo offers cutting-edge AMD diagnostic and treatment services, including gene therapies and anti-VEGF treatments. The city’s aging population and advanced healthcare infrastructure make it a focal point for AMD management, with early detection programs and research initiatives supporting market growth.

Kansai AMD Market

Kansai, including Osaka, Kyoto, and Kobe, is home to renowned ophthalmic institutes and pharmaceutical companies like Santen Pharmaceutical. The region is a hub for regenerative medicine and retinal treatment trials, supporting a wide range of therapeutic options for AMD patients.

Aichi AMD Market

Centered around Nagoya, Aichi Prefecture is becoming an important AMD care center. Well-established clinics equipped with advanced imaging technologies enable early detection of wet and dry AMD. Increasing awareness of eye health and availability of anti-VEGF therapies are driving regional market growth.

Other Key Regions

Kanagawa, Saitama, Hyogo, Chiba, Hokkaido, Fukuoka, Shizuoka: Growing urban populations and rising awareness contribute to increasing AMD diagnosis and treatment.

👉 For deeper analysis, detailed segment data, and company insights: 🔗 Request Customization Report

Market Segmentation

By Disease Type:

Dry AMD

Wet AMD

By Product:

Eylea

Lucentis

Beovu

Others

By Distribution Channel:

Hospital Pharmacy

Specialty Pharma

Online Pharmacy

By City/Region:

Tokyo

Kansai

Aichi

Kanagawa

Saitama

Hyogo

Chiba

Hokkaido

Fukuoka

Shizuoka

Key Players

F. Hoffmann-La Roche Ltd.

Bayer AG

AbbVie

GSK Plc

Novartis AG

Regeneron Pharmaceuticals

Bausch Health Companies Inc.

Alimera Sciences Inc.

These companies are focusing on innovative therapies, clinical trials, and strategic partnerships to strengthen their presence in the Japanese AMD market.

Future Outlook: 2025–2033

The Japan AMD market is poised for steady growth at a CAGR of 6.11%, supported by:

Expanding elderly population and rising AMD prevalence

Technological advancements in diagnostics and telemedicine

Introduction of gene therapies and novel anti-VEGF treatments

Government support for healthcare innovation and reimbursement optimization

With increasing public awareness, improved accessibility, and ongoing innovation, Japan is expected to maintain a robust AMD care ecosystem, ensuring better patient outcomes and sustained market expansion.

Note: If you need details, data, or insights not covered in this report, we are glad to assist. Through our customization service, we will collect and deliver the information you require, tailored to your specific needs. Share your requirements with us, and we will update the report to align with your expectations.